Population pharmacokinetic modeling of abacavir in HIV-exposed neonates and children with HIV-1 using data from the IMPAACT 2019 and PETITE studies
Abacavir (ABC) is one of the primary HIV nucleoside reverse transcriptase inhibitors used in pediatric antiretroviral therapy, yet optimal dosing in neonates and infants is challenging because of rapid developmental changes that influence its pharmacokinetics (PK). In this work, a previously developed pediatric population pharmacokinetic (PopPK) model for ABC was refined to extend its applicability to neonates and young infants by incorporating maturation-related processes and newly available...